VIICTR
Profiles
ORIT
Pediatrics CRA
Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. J Clin Oncol. 2015 Sep 01; 33(25):2780-8.
View in:
PubMed
subject areas
Adjuvants, Immunologic
Adult
Aged
Aged, 80 and over
Antineoplastic Agents
Chills
Fatigue
Female
Fever
Granulocyte-Macrophage Colony-Stimulating Factor
Herpesvirus 1, Human
Humans
Immunotherapy
Injections, Intralesional
Male
Melanoma
Middle Aged
Neoplasm Staging
Odds Ratio
Oncolytic Virotherapy
Oncolytic Viruses
Skin Neoplasms
Survival Analysis
Time Factors
Treatment Outcome
United States
authors with profiles
MERRICK I ROSS